ICON Public (NASDAQ:ICLR) PT Lowered to $295.00 at Truist Financial

ICON Public (NASDAQ:ICLR - Free Report) had its price target cut by Truist Financial from $363.00 to $295.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the medical research company's stock.

A number of other equities research analysts also recently weighed in on ICLR. Robert W. Baird downgraded shares of ICON Public from an "outperform" rating to a "neutral" rating and set a $340.00 price objective for the company. in a research report on Thursday. The Goldman Sachs Group dropped their price target on ICON Public from $370.00 to $280.00 and set a "buy" rating on the stock in a research report on Friday. Leerink Partners reduced their price objective on ICON Public from $376.00 to $270.00 and set an "outperform" rating for the company in a research report on Friday. StockNews.com lowered ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Finally, Leerink Partnrs upgraded ICON Public to a "strong-buy" rating in a research note on Wednesday, September 18th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, ICON Public has an average rating of "Moderate Buy" and an average price target of $304.27.

ICON Public Stock Up 4.5 %

NASDAQ:ICLR traded up $10.03 during mid-day trading on Monday, reaching $230.50. The stock had a trading volume of 2,292,563 shares, compared to its average volume of 628,728. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The company has a market capitalization of $19.02 billion, a price-to-earnings ratio of 26.86, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. ICON Public has a 1-year low of $220.01 and a 1-year high of $347.72. The stock's 50 day simple moving average is $295.86 and its two-hundred day simple moving average is $309.61.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm posted $3.10 earnings per share. ICON Public's revenue was down 1.2% compared to the same quarter last year. Equities analysts anticipate that ICON Public will post 14.53 EPS for the current year.

Institutional Investors Weigh In On ICON Public

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICLR. Liontrust Investment Partners LLP raised its position in ICON Public by 19.5% in the second quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company's stock worth $37,531,000 after acquiring an additional 19,546 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company's stock worth $30,016,000 after purchasing an additional 13,163 shares in the last quarter. Whittier Trust Co. lifted its stake in ICON Public by 12.3% during the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company's stock valued at $1,155,000 after purchasing an additional 441 shares during the last quarter. Sara Bay Financial bought a new stake in ICON Public during the third quarter worth approximately $1,143,000. Finally, Motco grew its position in ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company's stock worth $1,304,000 after buying an additional 59 shares during the last quarter. Institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.